1.71
+0.02(+1.18%)
Currency In USD
Address
7210 Frederick-Banting
Montreal, QC H4S 2A1
Canada
Phone
857 412 7018
Website
Sector
Healthcare
Industry
Biotechnology
Employees
129
First IPO Date
June 19, 2020
| Name | Title | Pay | Year Born |
| Mr. Steve Forte CPA | President, Chief Financial Officer, Chief Executive Officer & Director | 631,996 | 1979 |
| Dr. Michael Zinda Ph.D. | Executive Vice President & Chief Scientific Officer | 661,153 | 1971 |
| Mr. Philip Herman | Executive Vice President, Chief Commercial & Portfolio Development Officer | 0 | 1979 |
| Ms. Sandra Alves | Senior Vice President & Chief Accounting Officer | 0 | 1979 |
| Mr. Daniel Belanger | Executive Vice President of Human Resources | 0 | N/A |
| Dr. Agnel Sfeir Ph.D. | Co-Founder | 0 | N/A |
| Dr. Daniel Durocher Ph.D. | Co-Founder | 0 | N/A |
| Dr. Frank Sicheri Ph.D. | Co-Founder | 0 | N/A |
| Dr. Joseph P. O'Connell M.D. | Executive Vice President of Clinical Development and Medical Affairs | 0 | 1954 |
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.